SCIREX Corporation announced today the promotion of Sharon V. Medendorp, MPH, to the position of Executive Vice President and General Manager, Advanced Development, reporting to James D. Utterback, CEO. In this role, Ms. Medendorp will be responsible for the oversight of the Advanced Development group at SCIREX, which includes the Clinical Trial Management, Biometrics and Scientific & Medical Management groups.
SCIREX Corporation announced today the promotion of Sharon V. Medendorp, MPH, to the position of Executive Vice President and General Manager, Advanced Development, reporting to James D. Utterback, CEO. In this role, Ms. Medendorp will be responsible for the oversight of the Advanced Development group at SCIREX, which includes the Clinical Trial Management, Biometrics and Scientific & Medical Management groups. Ms. Medendorp had been Senior Vice President of Biometrics. Among her priorities in her new role will be important initiatives involving globalizing clinical operations and a continued emphasis on superior client service and scientific excellence.
A nine-year veteran of SCIREX, Ms. Medendorp joined the company in 1997 as Director of Statistics and quickly established a successful track record in managing multidisciplinary teams of research professionals. In addition to in-depth process and broad operational and industry knowledge, she has demonstrated the ability to build and maintain strong client relationships. Characteristically, she attributes a large part of her success to the talented group of SCIREX professionals supporting her at all levels.
Prior to joining SCIREX in 1997, Ms. Medendorp was a Lead Biostatistician for the Department of Biostatistics at the Cleveland Clinic. She has co-authored over 70 papers in medical and statistical journals and has extensive consulting experience. She has also taught statistics to medical professionals for continuing education. Ms. Medendorp holds a B.S. in Mathematics from Calvin College and an M.P.H. in Biostatistics from the University of Michigan.
About SCIREX
SCIREX Corporation (www.scirex.com) is an industry leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industry. SCIREX provides clinical trial management, drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions including IVRS, EDC and SIMSTM (Study Information Management System). SCIREX brings experience from more than 1,000 clinical trials involving well over 135,000 patients in most major therapeutic areas, with specific expertise in pain and inflammation, and neurological and psychiatric disorders. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc. (NYSE: OMC) (www.omnicomgroup.com).
